May 2018
Kempen is pleased to announce the successful EUR 77.5 million capital increase via an accelerated bookbuild offering by Mithra
Mithra Pharmaceuticals is a company focused on the development, manufacturing and commercialisation of drugs and generic products dedicated to Women’s Health. Mithra specialises in four different domains: contraception and fertility, menopause and osteoporosis, gynecological infections and female cancers. Its two lead development candidates Estelle and Donesta are built on Mithra’s unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its CDMO. The company is headquartered in Liège, Belgium